Jakavi 10mg Tablet

About Jakavi 10mg Tablet

Jakavi 10mg Tablet contains Ruxolitinib, a targeted anticancer medication belonging to the kinase inhibitor class, used to treat myelofibrosis, a rare bone marrow disorder that affects normal blood cell production, and polycythemia vera, a blood cancer characterized by excessive production of red blood cells in patients who are resistant to or unable to tolerate hydroxyurea. It is also approved for the treatment of acute and chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older who have not responded adequately to steroid therapy or other systemic treatments. Ruxolitinib works by blocking specific signaling pathways that promote abnormal cell growth and inflammation, helping to reduce symptoms and improve disease control. Patients should not use Jakavi 10mg Tablet if they are allergic to Ruxolitinib or any of its ingredients. Before starting treatment, it is important to inform your healthcare provider about any history of tuberculosis, hepatitis B or C infection, liver disease, kidney problems, or dialysis treatment. Common side effects may include dizziness, headache, low blood cell counts, bruising, bleeding, and swelling of the face or body. Regular blood tests and medical monitoring are essential during treatment to assess blood counts and detect potential complications early. Jakavi 10mg Tablet plays an important role in the management of complex hematological conditions, helping improve symptom control and overall quality of life.